YS Biopharma Files 6-K with FY2024 Nine-Month Financials
Ticker: LSBWF · Form: 6-K · Filed: Apr 19, 2024 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Ys Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | Apr 19, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-results, 6-K, foreign-private-issuer
TL;DR
YS Bio dropped its Q3 FY24 results, check the 6-K for the deets.
AI Summary
YS Biopharma Co., Ltd. filed a Form 6-K on April 19, 2024, to report its unaudited financial results for the first nine months of its fiscal year 2024. The filing includes a press release detailing these results.
Why It Matters
This filing provides investors with an update on YS Biopharma's financial performance for the majority of its fiscal year, offering insights into its operational and financial health.
Risk Assessment
Risk Level: medium — As a foreign private issuer reporting unaudited interim results, there's inherent uncertainty and less regulatory scrutiny compared to audited annual reports.
Key Numbers
- FY2024 — Fiscal Year (Reporting period for the financial results)
Key Players & Entities
- YS Biopharma Co., Ltd. (company) — Registrant
- 001-41598 (company) — Commission file number
- 20240419 (date) — Filing date
- 2024 (date) — Fiscal year
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose is to report the unaudited financial results for the first nine months of YS Biopharma's fiscal year 2024.
What is the filing date of this report?
The filing date is April 19, 2024.
What is the commission file number for YS Biopharma?
The commission file number is 001-41598.
Which exhibit contains the financial results?
Exhibit 99.1 contains the press release announcing the unaudited financial results for the first nine months of fiscal year 2024.
What is the fiscal year end for YS Biopharma?
The fiscal year end for YS Biopharma is March 31.
Filing Stats: 178 words · 1 min read · ~1 pages · Grade level 9.6 · Accepted 2024-04-19 08:03:54
Filing Documents
- ea0204144-6k_ysbio.htm (6-K) — 11KB
- ea020414401ex99-1_ysbio.htm (EX-99.1) — 94KB
- 0001213900-24-034266.txt ( ) — 106KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission file number: 001-41598 YS BIOPHARMA CO., LTD. (Exact name of registrant as specified in its charter) Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, PRC Tel: 010-89202086 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F EXHIBITS Exhibit No. Description 99.1 Press Release – YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 1 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. YS Biopharma Co., Ltd. By: /s/ Hui Shao Name: Hui Shao Title: Director and Chief Executive Officer Date: April 19, 2024 2